Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer”

135 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 135 results

Large-scale testing (Phase 3)Ended earlyNCT01303679
What this trial is testing

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Who this might be right for
First Line Metastatic Breast Cancer
ARCAGY/ GINECO GROUP 117
Testing effectiveness (Phase 2)Active Not RecruitingNCT04576455
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Who this might be right for
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 303
Early research (Phase 1)Looking for participantsNCT05870579
What this trial is testing

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 48
Testing effectiveness (Phase 2)UnknownNCT04488107
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c

Who this might be right for
Breast Neoplasms
Ahon Pharmaceutical Co., Ltd. 78
Early research (Phase 1)Active Not RecruitingNCT03725436
What this trial is testing

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Who this might be right for
Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+12 more
M.D. Anderson Cancer Center 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT04053322
What this trial is testing

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Who this might be right for
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancera Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
UNICANCER 172
Early research (Phase 1)Active Not RecruitingNCT04288089
What this trial is testing

H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

Who this might be right for
Receptors, EstrogenGenes, Erbb-2Breast Neoplasms
Eisai Inc. 31
Early research (Phase 1)Ended earlyNCT03816839
What this trial is testing

Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)

Who this might be right for
Breast Cancer
Sanofi 10
Early research (Phase 1)Ended earlyNCT02384746
What this trial is testing

Phase I Study of the Combination of MLN9708 and Fulvestrant

Who this might be right for
Breast Cancer
Dartmouth-Hitchcock Medical Center 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT04214288
What this trial is testing

Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

Who this might be right for
Advanced ER-Positive HER2-Negative Breast Cancer
AstraZeneca 240
Not applicableEnded earlyNCT06126003
What this trial is testing

Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

Who this might be right for
Breast Cancer
BioCorteX Inc 2
Testing effectiveness (Phase 2)Study completedNCT01698918
What this trial is testing

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast Cancer
Novartis Pharmaceuticals 202
Large-scale testing (Phase 3)Study completedNCT01626222
What this trial is testing

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 301
Not applicableUnknownNCT02875951
What this trial is testing

Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer

Who this might be right for
ER Positive, HER2 Negative Breast Cancer Neoplasms
KU Leuven 100
Testing effectiveness (Phase 2)Study completedNCT05054374
What this trial is testing

Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Who this might be right for
Breast CancerBreast Cancer Stage IVHER2-negative Breast Cancer+4 more
Memorial Sloan Kettering Cancer Center 6
Testing effectiveness (Phase 2)Study completedNCT03809988
What this trial is testing

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

Who this might be right for
Breast CancerAdvanced Breast CancerHormone Receptor Positive Tumor+1 more
MedSIR 198
Testing effectiveness (Phase 2)UnknownNCT04571437
What this trial is testing

Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)

Who this might be right for
Breast CancerEstrogen Receptor-positive Breast CancerMetastatic Breast Cancer
Cairo University 204
Testing effectiveness (Phase 2)Looking for participantsNCT06993844
What this trial is testing

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsAdvanced Breast Cancer
Ensem Therapeutics 233
Early research (Phase 1)Active Not RecruitingNCT05654532
What this trial is testing

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 100
Early research (Phase 1)Study completedNCT02338349
What this trial is testing

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

Who this might be right for
Advanced ER+, HER2-Negative Breast Cancer
Stemline Therapeutics, Inc. 57
Load More Results